News
RPHM
--
0.00%
--
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
IRVINE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, to...
GlobeNewswire · 09/09 13:12
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Focus Universal Inc. (NASDAQ: FCUV) shares jumped 108.2% to $10.62. The stock started trading on Nasdaq Capital Market yesterday.
Benzinga · 09/01 16:00
Regional Health Properties, AC Immune leads healthcare gainers; RenovoRx, Poseida Therapeutics among major losers
Gainers: Regional Health Properties (NYSE:RHE) +53%, AC Immune (NASDAQ:ACIU) +39%, Regencell Bioscience (NASDAQ:RGC) +29%, Qualigen Therapeutics (NASDAQ:QLGN) +19%, Reneo Pharmaceuticals (NASDAQ:RPHM) +17%. Losers: RenovoRx (NASDAQ:RNXT) -21%, Poseida Ther...
Seekingalpha · 08/31 15:11
60 Biggest Movers From Yesterday
Gainers Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 80.9% to close at $5.30 on Friday. The company recently reported a Q2 loss of $5.13 per share.
Benzinga · 08/30 09:18
NeuroMetrix, Reneo Pharmaceuticals leads healthcare gainers; Cassava Sciences, Applied Therapeutics among major losers
Gainers: NeuroMetrix (NASDAQ:NURO) +54%, Reneo Pharmaceuticals (NASDAQ:RPHM) +24%, Neoleukin Therapeutics (NASDAQ:NLTX) +21%, Chembio Diagnostics (NASDAQ:CEMI) +17%, InspireMD (NASDAQ:NSPR) +14%. Losers: Cassava Sciences (NASDAQ:SAVA) -28%, Applied Therape...
Seekingalpha · 08/27 15:06
Reneo Pharmaceuticals Shares Jump After CEO, CFO Disclose Purchases
MT Newswires · 08/27 13:47
Reneo Pharmaceuticals Inc (RPHM) President and CEO Gregory J. Flesher Bought $64,000 of Shares
GuruFocus News · 08/27 13:15
Sector Update: Health Care
MT Newswires · 08/27 13:02
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Benzinga · 08/27 11:35
Aisling Capital Management LP Buys Monte Rosa Therapeutics Inc, Nuvation Bio Inc, Biomea Fusion Inc
GuruFocus News · 08/20 18:38
Abingworth LLP Buys Vera Therapeutics Inc, Reneo Pharmaceuticals Inc
GuruFocus News · 08/18 13:38
Reneo Pharmaceuticals Q2 EPS $(0.43) Up From $(1.82) YoY
Reneo Pharmaceuticals (NASDAQ:RPHM) reported quarterly losses of $(0.43) per share. This is a 76.37 percent increase over losses of $(1.82) per share from the same period last year.
Benzinga · 08/11 10:05
NEA Management Company, LLC Buys Bright Health Group Inc, Monte Rosa Therapeutics Inc, Bill. ...
GuruFocus News · 08/02 16:38
BRIEF-Reneo Pharmaceuticals Says First Patient Has Been Dosed In Stride Study
reuters.com · 07/28 12:23
Dosing underway in Reneo Pharma's mid-stage STRIDE study
Reneo Pharmaceuticals (RPHM) announces that the first patient has been dosed in Phase 2b STRIDE study.The trial is designed to evaluate the efficacy and safety of REN001 for the treatment
Seekingalpha · 07/28 12:07
Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study
IRVINE, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today...
GlobeNewswire · 07/28 12:00
We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Simply Wall St. · 07/12 13:30
Reneo Pharmaceuticals Says Retiring Officer Cleared to Sell Stock in Lock-Up Waiver
MT Newswires · 07/09 15:14
Reneo Pharmaceuticals announces partial waiver of lock-up restriction
Reneo Pharmaceuticals (RPHM) has announced that the several underwriters of Reneo’s IPO, have agreed to waive the lock-up restriction with respect to 111,736 shares of common stock held by Wendy Johnson,
Seekingalpha · 07/09 12:54
Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction
SAN DIEGO, July 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, announced ...
GlobeNewswire · 07/09 12:00
Webull provides a variety of real-time RPHM stock news. You can receive the latest news about Reneo Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RPHM
Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the developing therapies for patients with rare genetic mitochondrial diseases. The Company is engaged in developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the source of energy for cellular processes. REN001 is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist that has been shown to transcription of genes involved in mitochondrial function and fatty acid oxidation (FAO). The Company is developing REN001 in the three rare genetic diseases that present with myopathy and have unmet medical need: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disease type V (McArdle disease). The Company has completed Phase I b clinical trial in patients with PMM to REN001. It is conducting open-label Phase I b clinical trials of REN001 with LC-FAOD and with McArdle disease.